Search

Your search keyword '"Yeoh, A.E.J. (Allen E. J.)"' showing total 2 results
Start Over Author "Yeoh, A.E.J. (Allen E. J.)"
2 results on '"Yeoh, A.E.J. (Allen E. J.)"'

1. Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes

Author

Rooij, J.D. (Johan) de, Branstetter, C. (Cristyn), Ma, J. (Jing), Li, Y. (Yongjin), Walsh, M.P. (Michael P), Cheng, J. (Jinjun), Obulkasim, A. (Askar), Dang, J. (Jinjun), Easton, J. (John), Verboon, P. (Peter), Mulder, H.L. (Heather L), Zimmermann, M. (Martin), Koss, C. (Cary), Gupta, P. (Pankaj), Edmonson, M. (Michael), Rusch, M. (Michael), Lim, J.Y.S. (Joshua Yew Suang), Reinhardt, K. (Katarina), Pigazzi, M. (Martina), Song, G. (Guangchun), Yeoh, A.E.J. (Allen E. J.), Shih, L.-Y. (Lee-Yung), Liang, D. (Der), Halene, S. (Stephanie), Krause, D.S. (Diane S), Zhang, J. (Jinghui), Downing, J.R. (James), Locatelli, F. (Franco), Reinhardt, D. (Dirk), Heuvel-Eibrink, M.M. (Marry) van den, Zwaan, C.M. (Michel), Fornerod, M.W.J. (Maarten), Gruber, T.A. (Tanja A), Rooij, J.D. (Johan) de, Branstetter, C. (Cristyn), Ma, J. (Jing), Li, Y. (Yongjin), Walsh, M.P. (Michael P), Cheng, J. (Jinjun), Obulkasim, A. (Askar), Dang, J. (Jinjun), Easton, J. (John), Verboon, P. (Peter), Mulder, H.L. (Heather L), Zimmermann, M. (Martin), Koss, C. (Cary), Gupta, P. (Pankaj), Edmonson, M. (Michael), Rusch, M. (Michael), Lim, J.Y.S. (Joshua Yew Suang), Reinhardt, K. (Katarina), Pigazzi, M. (Martina), Song, G. (Guangchun), Yeoh, A.E.J. (Allen E. J.), Shih, L.-Y. (Lee-Yung), Liang, D. (Der), Halene, S. (Stephanie), Krause, D.S. (Diane S), Zhang, J. (Jinghui), Downing, J.R. (James), Locatelli, F. (Franco), Reinhardt, D. (Dirk), Heuvel-Eibrink, M.M. (Marry) van den, Zwaan, C.M. (Michel), Fornerod, M.W.J. (Maarten), and Gruber, T.A. (Tanja A)

Abstract

Acute megakaryoblastic leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) in which cells morphologically resemble abnormal megakaryoblasts. While rare in adults, AMKL accounts for 4–15% of newly diagnosed childhood AML cases. AMKL in individuals without Down syndrome (non-DS-AMKL) is frequently associated with poor clinical outcomes. Previous efforts have identified chimeric oncogenes in a substantial number of

Published
2017
Full Text
View/download PDF

2. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: A retrospective international study

Author

Inaba, H. (Hiroto), Zhou, Y. (Yinmei), Abla, O. (Oussama), Adachi, S. (Susumu), Auvrignon, A. (Anne), Beverloo, H.B. (Berna), Bont, E.S.J.M. (Eveline) de, Chang, T.-T. (Tai-Tsung), Creutzig, U., Dworzak, M.N. (Michael), Elitzur, S. (Sarah), Fynn, A. (Alcira), Forestier, E. (Erik), Hasle, H. (Henrik), Liang, D.-C. (Der-Cherng), Lee, V. (Vincent), Locatelli, F. (Franco), Masetti, R. (Riccardo), Moerloose, B. (Barbara) de, Reinhardt, D. (Dirk), Rodriguez, L. (Laura), Roy, N. (Nadine) van, Shen, S. (Shuhong), Taga, T. (Takashi), Tomizawa, D. (Daisuke), Yeoh, A.E.J. (Allen E. J.), Zimmermann, M. (Martin), Raimondi, S.C. (Susana), Inaba, H. (Hiroto), Zhou, Y. (Yinmei), Abla, O. (Oussama), Adachi, S. (Susumu), Auvrignon, A. (Anne), Beverloo, H.B. (Berna), Bont, E.S.J.M. (Eveline) de, Chang, T.-T. (Tai-Tsung), Creutzig, U., Dworzak, M.N. (Michael), Elitzur, S. (Sarah), Fynn, A. (Alcira), Forestier, E. (Erik), Hasle, H. (Henrik), Liang, D.-C. (Der-Cherng), Lee, V. (Vincent), Locatelli, F. (Franco), Masetti, R. (Riccardo), Moerloose, B. (Barbara) de, Reinhardt, D. (Dirk), Rodriguez, L. (Laura), Roy, N. (Nadine) van, Shen, S. (Shuhong), Taga, T. (Takashi), Tomizawa, D. (Daisuke), Yeoh, A.E.J. (Allen E. J.), Zimmermann, M. (Martin), and Raimondi, S.C. (Susana)

Abstract

Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non-Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): -7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22; q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk - 7p abnormalities; poor risk - normal karyotypes, -7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, -13/13q-, and -15; and intermediate risk - others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results